Report Detail
Global (United States, European Union and China) Choroidal Neovascularization Drug Market Research Report 2019-2025
- RnM3370602 |
- 01 May, 2019 |
- Global |
- 124 Pages |
- QYResearch |
- Pharma & Healthcare
In 2019, the market size of Choroidal Neovascularization Drug is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Choroidal Neovascularization Drug.
This report studies the global market size of Choroidal Neovascularization Drug, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Choroidal Neovascularization Drug sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Cellphire, Inc.
Chrysalis BioTherapeutics, Inc.
Cleveland BioLabs, Inc.
Cumberland Pharmaceuticals, Inc.
Diffusion Pharmaceuticals Inc.
Eli Lilly and Company
GNI Group Ltd.
Humanetics Corporation
INSYS Therapeutics, Inc.
Meabco A/S
Neumedicines Inc.
Onconova Therapeutics, Inc.
PharmaIN Corporation
Pluristem Therapeutics Inc.
ProCertus BioPharm Inc.
RDD Pharma Ltd.
RedHill Biopharma Ltd.
RxBio, Inc.
Soligenix, Inc.
Market Segment by Product Type
AVMOC-001
BB-3
BBT-007
DG-3
Entolimod
EWA-001
Others
Market Segment by Application
Clinic
Hospital
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Choroidal Neovascularization Drug status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Choroidal Neovascularization Drug manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Choroidal Neovascularization Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Choroidal Neovascularization Drug Market Size Growth Rate by Type (2019-2025)
- 1.3.2 AVMOC-001
- 1.3.3 BB-3
- 1.3.4 BBT-007
- 1.3.5 DG-3
- 1.3.6 Entolimod
- 1.3.7 EWA-001
- 1.3.8 Others
- 1.4 Market Segment by Application
- 1.4.1 Global Choroidal Neovascularization Drug Market Share by Application (2019-2025)
- 1.4.2 Clinic
- 1.4.3 Hospital
- 1.4.4 Others
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Choroidal Neovascularization Drug Market Size
- 2.1.1 Global Choroidal Neovascularization Drug Revenue 2014-2025
- 2.1.2 Global Choroidal Neovascularization Drug Sales 2014-2025
- 2.2 Choroidal Neovascularization Drug Growth Rate by Regions
- 2.2.1 Global Choroidal Neovascularization Drug Sales by Regions 2014-2019
- 2.2.2 Global Choroidal Neovascularization Drug Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Choroidal Neovascularization Drug Sales by Manufacturers
- 3.1.1 Choroidal Neovascularization Drug Sales by Manufacturers 2014-2019
- 3.1.2 Choroidal Neovascularization Drug Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Choroidal Neovascularization Drug Revenue by Manufacturers (2014-2019)
- 3.2.2 Choroidal Neovascularization Drug Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Choroidal Neovascularization Drug Market Concentration Ratio (CR5 and HHI)
- 3.3 Choroidal Neovascularization Drug Price by Manufacturers
- 3.4 Key Manufacturers Choroidal Neovascularization Drug Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Choroidal Neovascularization Drug Market
- 3.6 Key Manufacturers Choroidal Neovascularization Drug Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 AVMOC-001 Sales and Revenue (2014-2019)
- 4.1.2 BB-3 Sales and Revenue (2014-2019)
- 4.1.3 BBT-007 Sales and Revenue (2014-2019)
- 4.1.4 DG-3 Sales and Revenue (2014-2019)
- 4.1.5 Entolimod Sales and Revenue (2014-2019)
- 4.1.6 EWA-001 Sales and Revenue (2014-2019)
- 4.1.7 Others Sales and Revenue (2014-2019)
- 4.2 Global Choroidal Neovascularization Drug Sales Market Share by Type
- 4.3 Global Choroidal Neovascularization Drug Revenue Market Share by Type
- 4.4 Choroidal Neovascularization Drug Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Choroidal Neovascularization Drug Sales by Application
6 United States
- 6.1 United States Choroidal Neovascularization Drug Breakdown Data by Company
- 6.2 United States Choroidal Neovascularization Drug Breakdown Data by Type
- 6.3 United States Choroidal Neovascularization Drug Breakdown Data by Application
7 European Union
- 7.1 European Union Choroidal Neovascularization Drug Breakdown Data by Company
- 7.2 European Union Choroidal Neovascularization Drug Breakdown Data by Type
- 7.3 European Union Choroidal Neovascularization Drug Breakdown Data by Application
8 China
- 8.1 China Choroidal Neovascularization Drug Breakdown Data by Company
- 8.2 China Choroidal Neovascularization Drug Breakdown Data by Type
- 8.3 China Choroidal Neovascularization Drug Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Choroidal Neovascularization Drug Breakdown Data by Company
- 9.2 Rest of World Choroidal Neovascularization Drug Breakdown Data by Type
- 9.3 Rest of World Choroidal Neovascularization Drug Breakdown Data by Application
- 9.4 Rest of World Choroidal Neovascularization Drug Breakdown Data by Countries
- 9.4.1 Rest of World Choroidal Neovascularization Drug Sales by Countries
- 9.4.2 Rest of World Choroidal Neovascularization Drug Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Cellphire, Inc.
- 10.1.1 Cellphire, Inc. Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Choroidal Neovascularization Drug
- 10.1.4 Choroidal Neovascularization Drug Product Introduction
- 10.1.5 Cellphire, Inc. Recent Development
- 10.2 Chrysalis BioTherapeutics, Inc.
- 10.2.1 Chrysalis BioTherapeutics, Inc. Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Choroidal Neovascularization Drug
- 10.2.4 Choroidal Neovascularization Drug Product Introduction
- 10.2.5 Chrysalis BioTherapeutics, Inc. Recent Development
- 10.3 Cleveland BioLabs, Inc.
- 10.3.1 Cleveland BioLabs, Inc. Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Choroidal Neovascularization Drug
- 10.3.4 Choroidal Neovascularization Drug Product Introduction
- 10.3.5 Cleveland BioLabs, Inc. Recent Development
- 10.4 Cumberland Pharmaceuticals, Inc.
- 10.4.1 Cumberland Pharmaceuticals, Inc. Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Choroidal Neovascularization Drug
- 10.4.4 Choroidal Neovascularization Drug Product Introduction
- 10.4.5 Cumberland Pharmaceuticals, Inc. Recent Development
- 10.5 Diffusion Pharmaceuticals Inc.
- 10.5.1 Diffusion Pharmaceuticals Inc. Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Choroidal Neovascularization Drug
- 10.5.4 Choroidal Neovascularization Drug Product Introduction
- 10.5.5 Diffusion Pharmaceuticals Inc. Recent Development
- 10.6 Eli Lilly and Company
- 10.6.1 Eli Lilly and Company Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Choroidal Neovascularization Drug
- 10.6.4 Choroidal Neovascularization Drug Product Introduction
- 10.6.5 Eli Lilly and Company Recent Development
- 10.7 GNI Group Ltd.
- 10.7.1 GNI Group Ltd. Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Choroidal Neovascularization Drug
- 10.7.4 Choroidal Neovascularization Drug Product Introduction
- 10.7.5 GNI Group Ltd. Recent Development
- 10.8 Humanetics Corporation
- 10.8.1 Humanetics Corporation Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Choroidal Neovascularization Drug
- 10.8.4 Choroidal Neovascularization Drug Product Introduction
- 10.8.5 Humanetics Corporation Recent Development
- 10.9 INSYS Therapeutics, Inc.
- 10.9.1 INSYS Therapeutics, Inc. Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Choroidal Neovascularization Drug
- 10.9.4 Choroidal Neovascularization Drug Product Introduction
- 10.9.5 INSYS Therapeutics, Inc. Recent Development
- 10.10 Meabco A/S
- 10.10.1 Meabco A/S Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Choroidal Neovascularization Drug
- 10.10.4 Choroidal Neovascularization Drug Product Introduction
- 10.10.5 Meabco A/S Recent Development
- 10.11 Neumedicines Inc.
- 10.12 Onconova Therapeutics, Inc.
- 10.13 PharmaIN Corporation
- 10.14 Pluristem Therapeutics Inc.
- 10.15 ProCertus BioPharm Inc.
- 10.16 RDD Pharma Ltd.
- 10.17 RedHill Biopharma Ltd.
- 10.18 RxBio, Inc.
- 10.19 Soligenix, Inc.
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Choroidal Neovascularization Drug Sales Channels
- 11.2.2 Choroidal Neovascularization Drug Distributors
- 11.3 Choroidal Neovascularization Drug Customers
12 Market Forecast
- 12.1 Global Choroidal Neovascularization Drug Sales and Revenue Forecast 2019-2025
- 12.2 Global Choroidal Neovascularization Drug Sales Forecast by Type
- 12.3 Global Choroidal Neovascularization Drug Sales Forecast by Application
- 12.4 Choroidal Neovascularization Drug Forecast by Regions
- 12.4.1 Global Choroidal Neovascularization Drug Sales Forecast by Regions 2019-2025
- 12.4.2 Global Choroidal Neovascularization Drug Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Choroidal Neovascularization Drug . Industry analysis & Market Report on Choroidal Neovascularization Drug is a syndicated market report, published as Global (United States, European Union and China) Choroidal Neovascularization Drug Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Choroidal Neovascularization Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
